Brief: Sab Biotherapeutics Initiates Ind-Enabling Glp Toxicology Study For Sab-142, Novel Immunotherapeutic For Type 1 Diabetes
21/11/2022 14:37
Nov 21 (Reuters) - SAB Biotherapeutics Inc SABS.O :
* SAB BIOTHERAPEUTICS INITIATES IND-ENABLING GLP TOXICOLOGY
STUDY
FOR SAB-142, NOVEL IMMUNOTHERAPEUTIC FOR TYPE 1 DIABETES
* SAB BIOTHERAPEUTICS INC - STUDY IS EXPECTED TO BE
COMPLETED IN
Q1 OF 2023
Source text for Eikon: ID:nGNX1YkgGN
Further company coverage: SABS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SAB Biotherapeutics
See all newsSAB Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
SAB Biotherapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Ferrari, Hawkeye 360, Micron Technology
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies
U.S. STOCKS ON THE MOVE-InspireMD, MiniMed, SoFi Technologies